COMMUNIQUÉS West-GlobeNewswire

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress
08/06/2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that Phase 1/2 clinical data for [...]
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
08/06/2026
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing Intravacc offers state-of-the-art analytical methods for identity, content, [...]
National Action Urged to Address Chronic Pain Crisis Among Women and Women Veterans in Canada
08/06/2026
HAMILTON, Ontario, June 08, 2026 (GLOBE NEWSWIRE) -- A newly released national report is calling for urgent, coordinated action to address chronic pain among women and women Veterans, outlining a roadmap for a pan- [...]
Appel À Une Action Nationale Pour Lutter Contre La Crise De La Douleur Chronique Chez Les Femmes Et Les Vétéranes Au Canada
08/06/2026
HAMILTON, Ontario, 08 juin 2026 (GLOBE NEWSWIRE) -- Un rapport national récemment publié appelle à une action urgente et coordonnée pour lutter contre la douleur chronique chez les femmes et les vétéranes et présente [...]
Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
08/06/2026
NORTHSTAR will evaluate the efficacy and safety of investigational oral gildeuretinol, designed to reduce the formation of toxic vitamin A dimers, a proven mechanism of Stargardt disease. The study will assess [...]
Koi Peptides Expands Research Catalog In June 2026
08/06/2026
Wyoming, WY, June 08, 2026 (GLOBE NEWSWIRE) -- Research peptide reference standards in the Koi Peptides laboratory catalog have broadened with the addition of new reference compounds for in vitro analytical use. Each [...]
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
08/06/2026
CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1 FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and Orphan Drug [...]
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
08/06/2026
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) [...]
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
08/06/2026
First regulatory approval for Sjögren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant [...]
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
08/06/2026
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission RENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq [...]
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
08/06/2026
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District [...]
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
08/06/2026
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opioid use disorder [...]
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
08/06/2026
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing Intravacc offers state-of-the-art analytical methods for identity, content, [...]
Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
08/06/2026
DALLAS, June 08, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today reiterates that the sunset of USDH and Felix Markets does not change its full-year 2026 guidance of $ [...]
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
08/06/2026
LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
08/06/2026
Mails Letter to Shareholders Detailing Strength of the Board’s Nominees and Momentum in Advancing Vaxart’s Value Creation Strategy Reinforces that the Dissident’s Nominees Have No Relevant Biotechnology or Public [...]
Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
08/06/2026
PDAOAI Platform Indexes 28 Million PubMed Abstracts on Qdrant; Introduces Manifold Folding to Solve the Infinity Problem in Biomedical Knowledge Retrieval AGOURA HILLS, CA, June 08, 2026 (GLOBE NEWSWIRE) -- Oncotelic [...]
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
08/06/2026
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England [...]
Hexiris Ophthalmics Marks Scientific Milestones, Launches Digital Presence, and Announces Hands-On Dry Lab at COS Annual Meeting, Montreal
08/06/2026
Canadian ophthalmic device company presents interventional glaucoma portfolio, launches digital presence, and invites surgeons to a hands-on OBi™ Core and OBi™ Gon dry lab at the COS Annual Meeting in Montreal DIEPPE, [...]

Pages